PAA
IART icon

Peregrine Asset Advisers’s Integra LifeSciences IART Stock Holding History

Peregrine Asset Advisers’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-40,531
Closed -$2.61M – 136
2018
Q2 		$2.61M Buy
+40,531
New +$2.51M 1.35% 24

Other funds holding IART

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Peregrine Asset Advisers's IART Position: Q3 2018 in Review

Peregrine Asset Advisers sold out of Integra LifeSciences (IART) in Q3 2018, closing a stake of 40,531 shares — an estimated $2.61M sold.

Peregrine Asset Advisers first reported a position in IART in Q2 2018 and held it in 1 quarter. The position peaked at $2.61M in Q2 2018. 249 funds tracked by Wall St. Rank hold IART as of Q3 2018.

  • Peregrine Asset Advisers reported no remaining Integra LifeSciences position as of Q3 2018 after selling out during the quarter.
  • Peregrine Asset Advisers sold 40,531 Integra LifeSciences shares in Q3 2018, an estimated $2.61M.
  • Peregrine Asset Advisers first reported a position in Integra LifeSciences in Q2 2018 and held it in 1 quarter.
  • Peregrine Asset Advisers's Integra LifeSciences position peaked at $2.61M in Q2 2018.
  • 249 funds tracked by Wall St. Rank held Integra LifeSciences as of Q3 2018.

Based on Peregrine Asset Advisers's 13F filing for Q3 2018, filed 13 Nov 2018.